Oxford Biomedica plc

Company Overview

Oxford BioMedica PLC is a CDMO company specializing in the research, development, and bioprocessing of viral vectors and cell therapy products.

The company operates into segments:

• Platform – this segment focus on activities that generate revenue through bioprocessing and process development services provided to external parties, such as partner programs like LentiVector® and AAV CDMOs business. Additionally, this segment encompasses our internal technological advancements and intellectual property related to the LentiVector® platform.
• Product – this segment involves both the clinical and pre-clinical stages of developing cell and gene therapy products, both in vivo (within the body) and ex vivo (outside the body). These products, known as gene therapeutics, are owned by the company.

The company addresses various diseases, including cancers, Parkinson’s, central nervous system disorders, and ocular conditions. Oxford BioMedica stands out in the industry by offering cutting-edge process development and manufacturing services to pharmaceutical and biotech firms operating in the rapidly expanding cell and gene therapy sector. The company is renowned for its viral vector manufacturing, encompassing lentiviral, AAV, and adenoviral vectors. It can create and manufacture commercially scalable cell and gene therapy products. The company also offers clinical-grade plasmid DNA for cell and gene therapy development.

Financial Highlights (FY 2023)

Company's Business Segments

• Bioprocessing/ Commercial development : This Platform segment which includes the revenue generating Bioprocessing, Process Development Activities for third parties and internal technology projects to develop new potentially Saleable Technology.
• Licence fees & incentives : This segment includes Fees, Incentives received from the clients for selling the Research activities.